Categories: News

BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Ahti Paananen

BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)

BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Ahti Paananen

This Company announcement contains information on the following management transactions:

  • Subscription of shares with warrants (TO1) 5 December 2022

____________________________________________

Person subject to the notification requirement

Name: Paananen Ahti

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20230803192300_8

____________________________________________

Transaction date: 2022-12-05

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 20,836 Unit price: 0.92 EUR

Aggregated transactions

(1): Volume: 20,836 Volume weighted average price: 0.92 EUR

Contact information:

Ilkka Kangasniemi, CEO
040 708 0307
ilkka.kangasniemi@bbs-artebone.fi

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

13 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

14 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago